Loading…
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $41M | $-10M | $-17M | $-10M | -25.1% | 7.4% | -35.5% |
| 2024 | $38M | $-20M | $-27M | $-14M | -32.5% | 2.9% | -27.3% |
| 2023 | $37M | $-31M | $-37M | $-27M | -40.9% | -11.4% | -22.5% |
| 2022 | $41M | $-26M | $-47M | $-56M | -47.5% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 41.42 | 36.68 | 37.74 | 40.52 |
| Operating Revenue | - | 41.42 | 36.68 | 35.98 | 38.69 |
| Cost Of Revenue | - | 23.94 | 26.39 | 30.51 | 27.08 |
| Gross Profit | - | 17.48 | 10.30 | 7.23 | 13.44 |
| Operating Expense | - | 46.33 | 41.50 | 33.38 | 30.42 |
| Research And Development | - | 7.74 | 5.57 | 2.76 | 2.20 |
| Selling General And Administration | - | 37.45 | 34.78 | 29.47 | 27.07 |
| Total Expenses | - | 70.28 | 67.88 | 63.89 | 57.50 |
| Operating Income | - | -28.86 | -31.20 | -26.15 | -16.98 |
| Total Operating Income As Reported | - | -49.66 | -35.56 | -26.15 | -16.98 |
| EBITDA | - | -25.69 | -30.58 | -19.57 | -10.15 |
| Normalized EBITDA | - | -4.89 | -25.40 | -19.57 | -10.63 |
| EBIT | - | -28.86 | -36.24 | -26.15 | -16.49 |
| Interest Expense | - | - | 0.83 | 0.69 | 0.71 |
| Net Interest Income | - | 0.21 | -0.83 | -0.69 | -0.71 |
| Other Non Operating Income Expenses | -0.04 | 0.06 | 0.14 | - | - |
| Other Income Expense | -0.04 | -20.75 | -5.05 | - | 0.48 |
| Interest Expense Non Operating | - | - | 0.83 | 0.69 | 0.71 |
| Net Non Operating Interest Income Expense | - | 0.21 | -0.83 | -0.69 | -0.71 |
| Pretax Income | - | -49.39 | -37.08 | -26.83 | -17.20 |
| Tax Provision | - | -1.92 | -0.30 | -0.09 | 0.06 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.81 | -0.04 | 0 | 0.10 |
| Net Income Continuous Operations | - | -47.47 | -36.78 | -26.74 | -17.26 |
| Net Income From Continuing And Discontinued Operation | - | -47.47 | -36.78 | -26.74 | -17.26 |
| Net Income From Continuing Operation Net Minority Interest | - | -47.47 | -36.78 | -26.74 | -17.26 |
| Net Income | - | -47.47 | -36.78 | -26.74 | -17.26 |
| Net Income Common Stockholders | - | -47.47 | -36.78 | -26.74 | -17.26 |
| Net Income Including Noncontrolling Interests | - | -47.47 | -36.78 | -26.74 | -17.26 |
| Normalized Income | - | -27.48 | -31.63 | -26.74 | -17.64 |
| Diluted NI Availto Com Stockholders | - | -47.47 | -36.78 | -26.74 | -17.26 |
| Basic Average Shares | - | 28.08 | 31.82 | 46.75 | 53.48 |
| Diluted Average Shares | - | 28.08 | 31.82 | 46.75 | 53.48 |
| Reconciled Depreciation | - | 3.16 | 5.66 | 6.58 | 6.34 |
| Reconciled Cost Of Revenue | - | 21.93 | 21.88 | 25.08 | 21.88 |
| Total Unusual Items | - | -20.80 | -5.19 | 0 | 0.48 |
| Total Unusual Items Excluding Goodwill | - | -20.80 | -5.19 | 0 | 0.48 |
| Special Income Charges | - | -20.80 | -5.19 | 0 | 0.48 |
| Other Special Charges | - | - | 0.82 | - | -0.48 |
| Impairment Of Capital Assets | 0 | 20.80 | 4.36 | 0 | - |
| Depreciation Amortization Depletion Income Statement | - | 1.15 | 1.15 | 1.15 | 1.15 |
| Depreciation And Amortization In Income Statement | - | 1.15 | 1.15 | 1.15 | 1.15 |
| General And Administrative Expense | - | 28.30 | 25.45 | 23.15 | 20.32 |
| Other Gand A | - | 28.30 | 25.45 | 23.15 | 20.32 |
| Total Other Finance Cost | 0.59 | -0.21 | 0.83 | - | - |
| Selling And Marketing Expense | - | 9.15 | 9.33 | 6.32 | 6.75 |
| Otherunder Preferred Stock Dividend | 0 | - | - | - | - |
| Amortization | - | 1.15 | 1.15 | 1.15 | 1.15 |
| Amortization Of Intangibles Income Statement | - | 1.15 | 1.15 | 1.15 | 1.15 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Alpha Teknova, Inc.this co. | TKNO | $291M | -16.87 | 4.23 | -25.1% | -30.89 |
| DiaMedica Therapeutics Inc. | DMAC | $315M | - | 5.61 | -58.4% | - |
| Electromed, Inc. | ELMD | $304M | 40.34 | 7.04 | 17.4% | 26.66 |
| Carlsmed, Inc. | CARL | $303M | -10.22 | 3.06 | -30.0% | -8.40 |
| OraSure Technologies, Inc. | OSUR | $287M | -4.18 |
| - |
| - |
| - |
| - |
| - |
| 0.84 |
| -20.2% |
| -1.74 |
| Niagen Bioscience, Inc. | NAGE | $279M | 16.04 | 3.64 | 22.7% | 13.78 |
| Quantum-Si incorporated | QSI | $279M | -2.75 | 1.27 | -46.0% | -2.81 |
| Eledon Pharmaceuticals, Inc. | ELDN | $278M | -6.09 | 3.43 | -56.3% | -3.08 |
| Entrada Therapeutics, Inc. | TRDA | $272M | -1.89 | 0.89 | -47.0% | -1.51 |
| Peer Median | - | -2.75 | 3.25 | -38.0% | -1.74 | |